

Indivior Publications 2017

Manuscripts

Treatment of Schizophrenia

1. Ivatori V, Gobburu J, Gopalakrishnan M, Zhang W, Jones JP III, Yongzhen L, Twumasi-Ankrah P, Heidbreder C, Laffont C. Exposure Response Analysis for a New Once a Month, Long Acting Risperidone. *J. Clin. Pharmacol.* 2017;83(7):1476-1498. <http://dx.doi.org/10.1111/bcp.13246>

Treatment of Opioid Use Disorder

1. Joshi A, Parris B, Liu Y, Heidbreder C, Gerk P, Halquist M. Quantitative determination of buprenorphine, naloxone and their metabolites in rat plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry. *Biomed Chromatogr.* 2017;31(2). <http://dx.doi.org/10.1002/bmc.3785>
2. Joshi A, Halquist M, Konsoula Z, Liu Y, Jones JP 3rd, Heidbreder C, Gerk PM. Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. *J Pharm Pharmacol.* 2017;69(1):23-31. <http://dx.doi.org/10.1111/jphp.12652>
3. Ruetsch C, Tkacz J, Nadipelli, VR, Brady BL, Ronquest N, Un H, Volpicelli J. Heterogeneity of Nonadherent Buprenorphine Patients: Subgroup Characteristics and Outcomes. *Am J Manag Care.* 2017;23(6):e172-e179. <https://www.ncbi.nlm.nih.gov/pubmed/28817294>
4. Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli, VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. *J Opioid Manag.* 2017;13(4), 207-220. <http://dx.doi.org/10.5055/jom.2017.0389>

White Papers

1. Heidbreder C. Driving innovation in addiction medicine. *Nat Rev Drug Discovery.* 2017. <https://biopharmadealmakers.nature.com/users/69929-indivior/posts/22450-driving-innovation-in-addiction-medicine>

Abstracts

Treatment of Opioid Use Disorder

2. Sabar U, Rycroft C, Ronquest N, Nadipelli V, Wollschlaeger B, Akehurst R. Analysis of humanistic burden reveals a need for opioid use disorder (OUD) disease-specific HRQoL instruments. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting. Boston, MA; May 2017.
3. Sabar U, Rycroft C, Ronquest N, Nadipelli V, Wollschlaeger B, Akehurst R. The economic burden of opioid use disorder (OUD): results of a structured literature review. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting. Boston, MA; May 2017.
4. Jiang H, Sheng L, Li Y, Gray F, Ling W, Hao W, Zhao M. Design Of a multi-centre, randomised, double-blind, placebo-controlled trial of buprenorphine/naloxone sublingual tablets (SUBOXONE®) for treatment of opioid dependence in China. The 2017 National Institute on Drug Abuse (NIDA) International Forum. Montreal, Canada; June 16, 2017.

5. Chilcoat H, Cicero TJ, Ellis MS. Understanding the use of buprenorphine without a prescription. Proceedings of the 79th Annual Meeting of the College on Problems of Drug Dependence (CPDD). Montreal, Canada; June 17-22, 2017.
6. Learned S, Haight B, Laffont C, Li D, Fudala P, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates efficacy, safety, and exposure/response relationship in opioid use disorder. Proceedings of the 79th Annual Meeting of the College on Problems of Drug Dependence (CPDD). Montreal, Canada; June 17-22, 2017.
7. Jones AK, Ngaimisi N, Gopalakrishnan M, Young M, Laffont CM. Long-term Exposure of RBP-6000 buprenorphine monthly formulation for the treatment of opioid use disorder: a combined population pharmacokinetic analysis. Proceedings of the Annual Meeting of the American Conference on Pharmacometrics (ACoP). Fort Lauderdale, FL; October 15-18, 2017.
8. Ngaimisi N, Gopalakrishnan M, Ivaturi V, Zhang W, Young M, Laffont CM. Exposure-response analyses to support dosing recommendations for RBP-6000 buprenorphine monthly formulation in subjects with opioid use disorder. Proceedings of the Annual Meeting of the American Conference on Pharmacometrics (ACoP). Fort Lauderdale, FL; October 15-18, 2017.
9. Haight B, Learned S, Laffont C, Li D, Fudala P, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates efficacy, safety, and exposure/response relationship in opioid use disorder: results of a phase 3 clinical trial. Proceedings of the Colloque International Addictions Toxicomanies Hépatites SIDA (ATHS). Biarritz, France; October 17-20, 2017.
10. Apelt S, Dematteis M, Benyamina A, Farah M, Mankabady B. A retrospective observational survey on buprenorphine/naloxone (SUBOXONE®) use in France. Proceedings of the Colloque International Addictions Toxicomanies Hépatites SIDA (ATHS). Biarritz, France; October 17-20, 2017.
11. Learned S, Haight B, Laffont C, Li D, Fudala P, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates efficacy, safety, and exposure/response relationship in adults with opioid use disorder: results of a phase 3 clinical trial. Proceedings of the Annual Meeting and Scientific Conference of the Canadian Society of Addiction Medicine (CSAM). Niagara Falls, Canada; October 19-21, 2017.
12. Wang X, Jiang H, Zhao M, Li J, Gray F, Sheng L, Li Y, Li X, Ling W, Li W, Hao W. Buprenorphine/naloxone sublingual tablets for the treatment of opioid dependence in Chinese citizens: a phase 3 randomized, double-blind, placebo-controlled, multi-center study. Proceedings of the Annual Meeting and Scientific Conference of the Canadian Society of Addiction Medicine (CSAM). Niagara Falls, Canada; October 19-21, 2017.
13. Apelt S, He J, Scherbaum N, Mankabady B. Analyses of all-cause mortality with buprenorphine/naloxone in the United Kingdom (UK). Proceedings of the Annual Meeting and Scientific Conference of the Canadian Society of Addiction Medicine (CSAM). Niagara Falls, Canada; October 19-21, 2017.
14. Haight B, Andorn A, Laffont C, Gray F, Young M, Jones A, Learned S, Li D, Heidbreder C. Efficacy, safety and exposure-response analyses for RBP-6000 once-monthly buprenorphine depot in subjects with opioid use disorder. Proceeding of the 19th Annual Meeting of the International Society of Addiction Medicine (ISAM). Abu Dhabi, United Arab Emirates; October 26-29, 2017.
15. Apelt S, Scherbaum N, He J, Mankabady B. Analyses of all-cause mortality with buprenorphine/naloxone in the United Kingdom (UK). Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Conference. Glasgow, Scotland; November 4-8, 2017.
16. Apelt S, Dematteis M, Banyamina A, Farah M, Mankabady B. A retrospective observational survey on buprenorphine-naloxone use in France. Proceedings of the International Society of

Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Conference. Glasgow, Scotland; November 4-8, 2017.

17. Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase 3 study. Proceedings of the Association for Medical Education and Research in Substance Abuse (AMERSA). Washington, DC; November 5-7, 2017.
18. Schmith V, Curd L, Lohmer L, Laffont C, Andorn A, Young M. Evaluation of RBP-6000 effects on QT interval during treatment for opioid use disorder (OUD). American Society for Clinical Pharmacology and Therapeutics (ASCPT). Washington, DC; March 16-18, 2017.
19. Learned S, Haight B, Laffont C, Li D, Fudala P, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates efficacy, safety, and exposure/response relationship in opioid use disorder. Proceedings of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Melbourne, Australia; November 12-15, 2017.
20. Haight B, Andorn A, Laffont C, Young M, Jones A, Learned S, Li D, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the Annual Meeting of the American College of Neuropsychopharmacology (ACNP). Palm Springs, CA; December 3-7, 2017.
21. Laffont CM, Ngaimisi E, Gopalakrishnan M, Young M, Haight B, Learned SM, Heidbreder C. Predictors of retention in treatment for opioid use disorder following administration of RBP-6000 vs. placebo. Proceedings of the 28th Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP). San Diego, CA; December 7-10, 2017.

Treatment of Schizophrenia

1. Graham J, Csernansky J, Fava M, Newcomer J, Andorn A, Shinde S, Muma G, Heidbreder C. Long-term safety and tolerability of a new monthly extended-release formulation of risperidone (RBP-7000) in the treatment of subjects with schizophrenia. Proceedings of the Annual Meeting of the American College of Neuropsychopharmacology (ACNP). Palm Springs, CA; December 3-7, 2017.